MedPath

Subcutaneous immunotherapy with PROLINEM -Asthma- Adults-Fase I

Phase 1
Conditions
Asthma
Registration Number
RPCEC00000139
Lead Sponsor
ational Center of Bioproducts (BioCen)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
20
Inclusion Criteria

1. Allergic asthmatic patients with a positive history of allergic symptoms caused by house dust, according to questionnaire

2. Positive skin test to Dermatophagoides siboney with wheal diameter greater than or equal to 3 mm and less than or equal to 7 mm (VALERGEN-DS 20 000 BU / mL) and negative skin test Blomia tropicalis and Dermatophagoides pteronyssinus, or positive with a diameter lower than that for DS.

3. Patients included in the study are patients diagnosed clinically as extrinsic asthmatics, which are classified as intermittent or persistent mild or moderate according to international guidelines for asthma (GINA, Global Initiative for Asthma)

4. Age between 18 and 45.

5. Any gender and color skin.

6. Patients express written consent to participate in our trial. 7.Pretreatment Supplementary examinations within the normal reference range of According to the institution.

Exclusion Criteria

1. Patients previously treated with immunotherapy with allergenic extracts in the previous five years.
2. Patients classified as severe persistent asthma.
3. Diagnosed autoimmune disease of any kind.
4. Generalized severe eczema.
5. Patients with tumor disease.
6. Patients treated with beta-blockers.
7. Patients where the use of adrenaline is contraindicated (hypertension).
8. Patients at least one year prior to the study required immunostimulant or immunosuppressive treatment (except corticosteroids), including interferons, cyclosporin A and natural immunomodulators (Vimang Biomodulina, etc.)
9. Patients who have suffered from bacterial meningitis, one year prior starting treatment .
10. Patients with a history of psychiatric disorders.
11. Lack of patient cooperation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath